Haleon plc (LON: HLN)
London
· Delayed Price · Currency is GBP · Price in GBX| Market Cap | 30.05B |
| Revenue (ttm) | 11.24B |
| Net Income (ttm) | 1.08B |
| Shares Out | 9.13B |
| EPS (ttm) | 0.12 |
| PE Ratio | 27.42 |
| Forward PE | 18.66 |
| Dividend | 0.06 (1.82%) |
| Ex-Dividend Date | Mar 14, 2024 |
| Volume | 39,617,998 |
| Open | 327.00 |
| Previous Close | 332.40 |
| Day's Range | 326.80 - 332.10 |
| 52-Week Range | 306.80 - 344.15 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | 36,600.00 (+11,024.62%) |
| Earnings Date | Aug 1, 2024 |
About Haleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops,... [Read more]
Financial Performance
In 2023, Haleon's revenue was 11.30 billion, an increase of 4.09% compared to the previous year's 10.86 billion. Earnings were 1.05 billion, a decrease of -1.04%.
Financial StatementsNews
GSK sale of remaining Haleon stake nets more than $1.5B
GSK nets £1.2bn after selling final stake in Sensodyne maker Haleon
Haleon was spun out of GSK as a standalone business listed on the London Stock Exchange in July 2022.
GSK raises $1.5 bln from offloading Haleon stake at a discount
GSK has raised 1.25 billion pounds ($1.52 billion) from selling its entire remaining stake in consumer healthcare firm Haleon, the British drugmaker said on Friday.
GSK sells off remaining stake in Haleon
The sale of its 4.2 per cent holding is expected to raise around £1bn
GSK intends to sell its remaining stake in Haleon
British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
GSK to sell entire Haleon stake
GSK (GSK) announces plans to sell its entire stake in consumer care company Haleon, following previous gradual reductions in ownership. Read more here.
Haleon: Pressures Are Temporary, But Closer To Fair Value
Haleon plc (HLN) Q1 2024 Earnings Call Transcript
Haleon plc (NYSE:NYSE:HLN) Q1 2024 Earnings Conference Call May 1, 2024 4:00 AM ETCompany ParticipantsSonya Ghobrial - Head, Investor RelationsTobias...
BUSINESS CLOSE: GSK raises guidance; Next exceeds forecasts; Aston Martin losses nearly double
Among the companies with reports and trading updates today are Next, GSK, Aston Martin Lagonda, Haleon, CVS Group, Smith & Nephew and Computacenter.
GSK ups 2024 guidance as HIV drugs and new vaccines boost its bottom line
The British drugmaker’s remaining 4.2% stake in its consumer health arm Haleon also boosted its bottom line, following its spin off in July 2022
Haleon's first-quarter revenue misses expectations
Consumer healthcare company Haleon's first-quarter revenue missed market estimates on Wednesday, due to retailer destocking in the U.S., and a cool down in demand for cold and flu medication after a s...
Haleon Keeps Outlook as Profits Rise
Haleon reported a 2% rise in underlying profits for the first quarter despite lower revenue, and maintained its full-year guidance and buyback plan.
Sensodyne maker Haleon to shut UK factory with loss of 435 jobs
The consumer healthcare group is aiming to close the site on a phased basis over the next two years.
Sensodyne-maker Haleon to shut UK manufacturing site, with more than 400 jobs hit
Consumer healthcare company Haleon is planning to shut down its manufacturing site in Britain by 2026, which will impact 435 jobs, a spokesperson told Reuters on Tuesday.
Companies Reporting: HSBC, Whitbread, Haleon, Apple
FTSE 350 and other selected companies reporting earnings for the week of 29th April include HSBC, Whitbread, Haleon and Apple
Dawn Allen Succeeds Tobias Hestler as CFO of Haleon
Consumer healthcare firm Haleon (HLN.L) announced on Wednesday the appointment of Dawn Allen as its new Chief Financial Officer, effective November 1st. Allen, at the age of 55, currently serves as CF...
Haleon names Dawn Allen as CFO
Consumer healthcare firm Haleon said on Wednesday that Dawn Allen has been appointed as its new chief financial officer, effective Nov. 1.
Warning: HLN is at high risk of cutting its dividend
Sensodyne partners with top dental colleges of India to drive education on oral health
As part of its #BeSensitiveToOralHealth initiative for World Oral Health Day, Sensodyne is hosting educational sessions with students across leading dental colleges in India NEW DELHI, March 20, 2024 ...
Pfizer will raise about $3.5 billion from the sale of part of its stake in consumer-healthcare business Haleon.
Pfizer will raise about $3.5 billion from the sale of part of its stake in consumer-healthcare business Haleon.
Pfizer to Raise Around $4.27 Billion From Haleon Shares Sale
Pfizer is raising around $4.27 billion from the sale of part of its stake in consumer-healthcare business Haleon.
Pfizer sells £3B of shares in Haleon
Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2B
Pfizer Inc (NYSE: PFE) plans to slash its stake to approximately 24% in Consumer healthcare giant Haleon Plc (NYSE: HLN) This move follows Pfizer’s earlier announcement that it will gradually divest...